We have developed a range of cutting-edge tests designed to help discover, analyse and screen cancer cells at every step of the disease
The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer. During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential […]
Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location. During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs). Metastat RGCC is […]
Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer. During the test, a sample of blood is analysed to identify the presence and concentration of CTC and their immunophenotype. Oncotrail […]
Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis. During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their […]
Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning. The test is designed as a follow-up test for patients who have cancer and are worried about […]
